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8 Abstract
9 Introduction Optimal risk factor control is integral to
10 managing patients with proven coronary heart disease
11 (CHD?) and for those at risk of coronary heart disease
12 (CHD-). The primary aim of the study was to assess the
13 success rate of reaching lipid risk factor targets in a mul-
14 tiple risk factor clinic.
15 Methods A retrospective audit was conducted in 488
16 patients (CHD+, n = 112; CHD-, n = 376) who attended
17 the Cardiovascular Risk Factor Clinic at Tallaght Hospital,
18 Dublin in 2009 and 2010.
19 Results Risk factor targets achieved in CHD? and
20 CHD- patients were LDLc (54/62 %), HDLc (67/67 %),
21 systolic blood pressure (35/38 %), diastolic blood pressure
22 (82/75 %), smoking cessation (27/26 %), BMI B 30 (39/
23 50 %) and normal waist circumference (27/39 %). Patients
24 not reaching LDLc targets were found to be receiving
25 fewer lipid-lowering drugs and having higher LDL levels
26 at the initial clinic visit than those reaching targets.
27 Discussion This retrospective audit highlights gaps in
28 achieving target lipid levels at a multiple risk factor clinic
29 level. High initial LDLc levels and lack of drug titration are
30 evident. Guideline changes, staff rotation, clinic visit fre-
31 quency and multiplicity of targets may be contributory.
32 More emphasis needs to be placed on education and
33 algorithm-based strategies to achieve better risk factor
34 control.
35
36 Keywords Risk factor audit  Lipid targets 
37 Cardiovascular risk factors  Coronary heart disease 
38 Obesity  Blood pressure
39Introduction
40Coronary heart disease (CHD) is a major cause of mor-
41bidity and mortality in the developed world. Many risk
42factors have been identified which have a strong associa-
43tion with CHD, such as raised low-density lipoprotein
44cholesterol levels (LDLc), reduced high-density lipoprotein
45cholesterol levels (HDLc), hypertension, diabetes, smoking
46and increased waist circumference [1–5]. Treating these
47risk factors is critical to reducing the burden of CHD.
48While controlled drug trials have yielded significant risk
49factor improvements resulting in reduced cardiovascular
50events, such successes are not equally matched in clinical
51practice [6]. Assessing risk factor modification in clinical
52practice may therefore help identify where problem areas
53exist. Exploring these areas and identifying their associa-
54tions may be important in achieving better risk factor
55control.
56Our aim was therefore to perform a retrospective audit
57of our risk factor clinic to identify how well risk factors
58were being controlled and examine if any patterns exist that
59might guide future interventions.
60Methods
61The management of CHD and its associated risk factors
62was assessed by a retrospective audit of patients (n = 488)
63attending the Cardiovascular Risk Factor Clinic at Tallaght
64Hospital in 2009 and 2010.
65Patients were referred, with or without pre-existing
66heart disease, to the clinic from their local G.P., other
67hospital services or the occupational health department at
68their place of work. The audit did not require ethical
69approval.
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70 CHD risk factors, including hypertension, abnormal
71 blood lipid profile, hyperglycemia, BMI and smoking were
72 recorded from each patient’s initial clinic visit (Initial) and
73 most recent (Latest) visits to the clinic (mean ± SD:
74 35 ± 31 months). In addition to the major cardiovascular
75 risk factors, age, gender, medication, family history and
76 waist circumference were also recorded. LDLc values were
77 calculated using the Friedewald formula [7] (LDLc = total
78 cholesterol – (triglyceride/2.12 ? HDLc)) and only used if
79 triglyceride levels were \ 4 mmol/l. The values for 12
80 patients could not be calculated because of triglyceride
81 values[ 4 mmol/l. Patients were subdivided into those
82 with coronary heart disease (CHD?, n = 112) and those
83 without coronary heart disease (CHD - , n = 376).
84 Unpaired t test and Fisher’s exact test were used to
85 detect the absolute and relative differences between the
86 CHD? and CHD- groups (JMP Version 4.0, SAS Institute
87 Inc., NC, USA). Data are presented as mean ± SD unless
88 otherwise stated.
89 Results
90 The average time interval between baseline and final visits
91 was 35 ± 31 months with 77 % of patients attending the
92 clinic for at least 1 year.
93 The risk factor levels of all patients at the initial visit are
94 outlined in Table 1. The CHD? group was significantly
95 older and received greater lipid-lowering therapies com-
96 pared to the CHD- group (p\ 0.0001). The mean total
97 cholesterol, LDLc and HDLc levels (males) were signifi-
98 cantly lower in the CHD? group compared to the CHD-
99 group (p\ 0.0001). The presence of diabetes and stroke
100 was significantly higher in the CHD? group. While mean
101 diastolic blood pressures were significantly lower in the
102 CHD? group, there was no significant difference in the
103 percentage of patients with a history of hypertension or
104 clinic-measured systolic blood pressures between the
105 groups. Smoking status, waist circumference and BMI
106 were not different between groups.
107 The impact of intervention in both groups attending the
108 risk factor clinic is outlined in Table 2 where comparison
109 of initial and latest clinic visits can be seen. Since targets
110 for LDLc changed during the period of audit, both new and
111 old target levels are included. There was a significant
112 increase in the percentage of patients in both groups
113 receiving lipid-lowering therapy at their latest clinic visit,
114 which was particularly evident in the CHD- group who
115 had\ 40 % lipid-lowering treatments at their initial visit.
116 90 % of patients taking lipid-lowering medication were
117 receiving statin monotherapy. 50 % of patients were pre-
118 scribed atorvastatin (10 mg 32 %, 20 mg 27 %, 40 mg
119 27 % and 14 % dose not documented), 24 % were
120prescribed rosuvastatin (10 mg 55 %, 20 mg 29 %, 40 mg
1219 % and 7 % dose not documented), 10 % were prescribed
122pravastatin (10 mg 18 %, 20 mg 39 %, 40 mg 36 % and
1237 % dose not documented) and 7 % were prescribed sim-
124vastatin (20 mg 44 %, 40 mg 20 % and 36 % dose not
125documented). The remaining 9 % of patients were taking
126other lipid therapies.
127There was a significant increase in the number of CHD-
128and CHD? patients reaching LDLc target levels (p\ 0.01)
129when the old LDLc target of\3.0 mmol/l was used, but no
130differences were observed when new target levels
131(\ 2.5 mmol/L) were used.
132The percentage of patients achieving HDL targets was
133unchanged from initial to latest visits. The percentage
134reaching systolic blood pressure targets levels was
135unchanged, whereas the percentage of patients reaching
136diastolic blood pressure targets (\ 85 mmHg) significantly
137improved in both groups of patients. The percentage of
138nonsmokers increased in both patient groups, but this only
139reached significance in the CHD- group. The percentage
Table 1 Baseline risk factor levels at initial clinic presentation
according to CHD status
Risk variable CHD? CHD- p
n = 112 n = 376
Age (years) 59 ± 11 51 ± 12 \0.0001
On lipid Tx 73 % 39 % \0.0001
Total cholesterol (mmol/L) 4.8 ± 1.2 5.5 ± 1.3 \0.0001
LDL (mmol/L) 2.7 ± 1.1 3.2 ± 1.1 \0.0001
HDL male (mmol/L) 1.2 ± 0.3 1.3 ± 0.4 \0.05
HDL female (mmol/L) 1.5 ± 0.3 1.6 ± 0.4 NS
Triglyceride (mmol/L) 1.9 ± 1.1 2.1 ± 2.4 NS
Hypertension history 43 % 41 % NS
Systolic BP (mmHg) 139 ± 20 142 ± 23 NS
Diastolic BP (mmHg) 82 ± 14 85 ± 15 \0.05
Smoking status
Yes 23 % 31 % NS
No 77 % 69 % NS
Diabetes history 14 % 6 % \0.05
Glucose (mmol/L) 5.9 ± 1.6 5.3 ± 0.7 \0.01
BMI (kg/m2) 31.1 ± 4.9 31.0 ± 6.1 NS
WC male (cm) 102.1 ± 11.4 102.7 ± 13.5 NS
WC female (cm) 97.3 ± 1.3 95.4 ± 1.3 NS
History of CVA 10 % 4 % \0.05
History of PVD 4 % 2 % NS
Unpaired t test and Fisher’s exact test were used to detect absolute
and relative differences between CHD? and CHD- groups. Data are
mean ± SD unless otherwise stated
LDLc low-density lipoprotein cholesterol, HDLc high-density lipo-
protein cholesterol, BP blood pressure, BMI body mass index, WC
waist circumference, CVA cerebrovascular accident, PVD peripheral
vascular disease.
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140 of patients in the CHD- group who achieved BMI and
141 waist circumference target levels was unchanged. How-
142 ever, the percentage of patients in the CHD? group who
143 achieved BMI and waist circumference target levels was
144 significantly reduced compared to the initial clinic visits.
145 The factors associated with achieving or not achieving
146 LDLc targets in both groups are outlined in Table 3. The
147 only notable factor in the CHD? group was that those
148 reaching LDLc targets had also a significantly greater
149 increase in HDLc levels. In contrast, in the CHD- group,
150 those achieving LDLc target levels were older, male, had
151 lower baseline LDLc levels and were on lipid-lowering
152 medication. Reaching LDLc targets did not relate to weight
153 changes.
154 Table 4 outlines the factors associated with reaching
155 HDLc targets in both groups. Patients in the CHD? group
156 achieving HDLc targets were older, had higher HDLc
157 levels initially and were on less lipid-lowering drugs when
158 initially reviewed.
159 In the CHD- group, the patients reaching HDLc targets
160 had significantly higher baseline HDLc levels and there
161 was a greater proportion of males than females. There was
162 also a significantly greater reduction in systolic blood
163 pressure in those reaching HDLc targets.
164 Discussion
165 This retrospective audit gives some insight into how car-
166 diovascular risk factors are being managed in clinical
167 practice. Given the high risk population involved, it is
168noteworthy that 87 % of patients with proven CHD were on
169lipid-lowering therapy and over 80 % had achieved LDLc
170levels \3.00 mmol/L with 54 % achieving LDLc levels
171below 2.50 mmol/l. These findings are not as good as pre-
172vious studies where 73 and 79 % of patients achieved target
173LDLc levels (\ 2.50 mmol/L) [8, 9]. However it must be
174noted that patient data recorded for the present study was
175based on older LDLc guidelines (\ 3.00 mmol/L).
176LDLc target achievement was similar to that observed in
177the EUROASPIRE studies where * 54 % of patients
178achieved target total cholesterol (\ 4.5 mmol/L) [10].
179Statin therapies were either not started or not uptitrated
180in 77 % of CHD- and 80 % of CHD? despite patients
181failing to achieve LDLc targets. Previous research also
182reports that in the majority of patients, statin doses remain
183unchanged regardless of improvements, or lack thereof, in
184LDLc control. [10] In the current study, 57 % of CHD?
185patients who were uptitrated achieved LDLc targets. This
186further emphasizes the need for clinicians to constantly
187review and uptitrate medication where possible.
188Age, gender, weight changes, blood pressure changes,
189percent on lipid-lowering treatment and drug doses were
190not influencing factors in reaching target LDLc levels in
191those with CHD. In patients without CHD, it is not
192surprising that factors such as age, male gender and
193initial LDLc levels were the significant factors associated
194with reaching targets as they would all be considered
195reasons to treat. Overall, the main explanation why some
196patients reached targets whereas others did not appeared
197to be better response to treatment as judged by the
198greater LDLc reductions and HDLc increases. 77 % of
Table 2 Number and percent of patients reaching risk factor targets for initial and latest visits according to the CHD status
Targets CHD? CHD-
Initial Latest p Initial Latest p
On lipid Tx 73 % 87 % \0.05 39 % 68 % \0.0001
New LDL target 42 (42 %) 54 (54 %) NS *140 (43 %) *204 (62 %) \0.0001
Old LDL target 63 (63 %) 81 (81 %) \0.01 *140 (43 %) *204 (62 %)
HDL C 1.0 M C 1.3 F 83 (74 %) 75 (67 %) NS 261 (71 %) 247 (67 %) NS
Sys BP\ 130 49 (44 %) 40 (35 %) NS 136 (36 %) 143 (38 %) NS
Dia BP\ 85 71 (64 %) 91 (82 %) \0.01 211 (56 %) 281 (75 %) \0.0001
Nonsmokers 86 (77 %) 93 (83 %) NS 260 (69 %) 290 (77 %) \0.05
BMI B 30 59 (53 %) 44 (39 %) \0.05 186 (50 %) 188 (50 %) NS
WC\ 102 M\ 88 F 38 (43 %) 24 (27 %) \0.05 128 (41 %) 122 (39 %) NS
Glucose\ 6.2 28 (80 %) 24 (69 %) NS 88 (84 %) 85 (81 %) NS
LDLc data for 12 patients could not be calculated (Friedewald) because of high triglyceride values. Unpaired t test and Fisher’s exact test were
used to detect absolute and relative differences between the initial and final visits
LDLc low-density lipoprotein cholesterol (new LDLc target based on\2.5 for CHD? and\3.0 for CHD-, old LDLc target\ 3.0 for CHD?).
HDLc high-density lipoprotein cholesterol, Sys BP systolic blood pressure, Dia BP diastolic blood pressure, BMI body mass index, WC waist
circumference, M male, F female
* New and old LDLc targets remain unchanged for patients without CHD
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199 patients attended the clinic for[1 year with an average
200 of four to five visits per patient. This should have given
201 ample time for lipid-lowering therapies and lifestyle
202 modifications to take effect. There were no differences in
203 the relative number of patients reaching LDLc targets
204 who attended for less than 12 months. Therefore, it is
205 unlikely that the duration of clinic attendance impacted
206 on the results.
207It is also noteworthy that many patients were referred to
208this clinic due to refractoriness to treatment, drug intoler-
209ances and having co-morbidities such as liver and renal
210disease which may limit aggressive treatment. In addition,
211since this is a multiple risk factor clinic, success at
212achieving some risk factor targets such as smoking cessa-
213tion and blood pressure control may have influenced the
214aggressiveness of lipid-lowering strategies. As patients
Table 3 Factors affecting the achievement of LDLc targets at the latest visit
LDL targets
CHD? p CHD- p
Reached Not reached Reached Not reached
n = 57 n = 48 n = 226 n = 136
Age (years) 62 ± 10 65 ± 10 NS 55 ± 12 51 ± 13 \0.01
Gender M:F 39:18 25:23 NS 111:115 48:88 \0.05
Initial LDL (mmol/L) 2.5 ± 1.2 3 ± 0.9 NS 3.0 ± 1.0 3.6 ± 1.2 \0.0001
LDLc D -14.5 % 8.8 % \0.01 -19.0 % 10.8 % \0.0001
HDLc D 8.9 % -3.1 % \0.05 -2.1 % 0.3 % NS
SBP D 0.2 % -1.0 % NS -2.6 % -1.3 % NS
DBP D -3.5 % -3.3 % NS -4.6 % -5.9 % NS
BMI D 1.7 % 1.1 % NS 1.2 % 1.8 % NS
WC D 3.3 % 4.6 % NS 2.2 % 1.6 % NS
On lipid Tx initial 74 % 69 % NS 45 % 29 % \0.01
On lipid Tx latest 92 % 79 % NS 77 % 51 % \0.0001
LDLc low-density lipoprotein cholesterol, HDLc high-density lipoprotein cholesterol, SBP systolic blood pressure, DBP diastolic blood pres-
sure. BMI body mass index, WC waist circumference. M male, F female, D mean percent change in risk factor from the initial visit to the latest
visit. Unpaired t test and Fisher’s exact test were used to detect absolute and relative differences between the initial and latest visits. Data are
mean ± SD unless otherwise stated. LDLc data for 12 patients could not be calculated because of high triglyceride levels
Table 4 Factors affecting the achievement of HDLc targets at the latest visit
HDL targets
CHD? p CHD- p
Reached Not reached Reached Not reached
n = 73 n = 32 n = 252 n = 110
Age (years) 65 ± 10 59 ± 9 \0.01 54 ± 12 52 ± 13 NS
Gender M:F 43:30 21:11 NS 124:128 35:75 \0.01
Initial HDL (mmol/L) 1.4 ± 0.3 1.1 ± 0.3 \0.0001 1.6 ± 0.4 1.2 ± 0.3 \0.0001
HDLc D 7.1 % -6.1 % \0.05 2.1 % -9.4 % \0.0001
LDLc D -4.8 % -1.5 % NS -7.5 % -8.4 % NS
SBP D -1.4 % 2.0 % NS -3.2 % 0.4 % \0.05
DBP D -4.8 % -0.3 % NS -5.9 % -3.3 % NS
BMI D 1.3 % 1.8 % NS 1.7 % 0.8 % NS
WC D 3.1 % 5.6 % NS 2.2 % 1.3 % NS
On lipid Tx initial 64 % 88 % \0.05 38 % 41 % NS
On lipid Tx latest 74 % 78 % NS 71 % 73 % NS
HDLc high-density lipoprotein cholesterol, LDLc low-density lipoprotein cholesterol, SBP systolic blood pressure, DBP diastolic blood pressure.
BMI body mass index, WC waist circumference, M male, F female, D mean percent change in risk factor from the initial visit to the latest visit.
Unpaired t test and Fisher’s exact test were used to detect absolute and relative differences between groups that reached and did not reach HDLc
targets. Data are mean ± SD unless otherwise stated
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215 attend the clinic usually on a 6-monthly or annual basis due
216 to limited clinic places, focus on one particular risk factor
217 may have been emphasized more than others.
218 HDLc is gaining increasing importance as an indepen-
219 dent cardiovascular risk factor and predictor for cardio-
220 vascular risk [11]. Its levels may improve using statin
221 therapy [12]. However, its manipulation to reduce cardio-
222 vascular events is being questioned [13]. According to the
223 guidelines set out by European Society of Cardiology,
224 HDL levels should be[1.0 mmol/L (40 mg/dL) in males
225 and[1.2 mmol/L (46 mg/dL) in females. In the present
226 study, approximately two-thirds of patients in the clinic had
227 HDLc target levels at baseline. There was no significant
228 change during clinic visits.
229 This reflects the high baseline levels and that statin
230 therapy, while having some beneficial effects on HDLc, is
231 insufficient to appropriately manage low HDLc levels [14].
232 Intensive lifestyle modification in conjunction with niacin
233 and fibrate intervention may improve HDLc status and
234 therefore improve risk factor status in patients with dysli-
235 pidemia [10, 11]. Such strategies need better
236 implementation.
237 Optimization of blood pressure-lowering medication
238 and weight loss are associated with significant reductions
239 in both systolic and diastolic blood pressure [15]. In the
240 present audit, diastolic blood pressure was well managed
241 with over three-quarters of patients reaching targets of
242 \85 mmHg. Patients with CHD had lower DBP compared
243 to those without CHD. This was more than likely due to the
244 fact that those patients diagnosed as having CHD were
245 already prescribed anti-hypertensive medication prior to
246 their initial clinic visit. Despite good diastolic blood pres-
247 sure control, systolic blood pressure control was disap-
248 pointing with just over one-third achieving targets of
249 \130 mmHg. This may reflect ongoing white coat effects
250 at clinic visits, despite underlying blood pressure
251 improvements [16]. Hence, the main focus in clinics had
252 been usage of 24 h blood pressure monitoring. These
253 results are similar to the findings of the latest EUROA-
254 SPIRE study which recorded that only 39 % of patients
255 achieved BP targets of 140/80 and 130/80 mmHg in
256 patients with diabetes [6]. Assessing the cardiovascular risk
257 factors as a whole and implementing earlier pharmaco-
258 logical and weight loss interventions before patients reach
259 a hypertensive state could help manage the increasing
260 burden of systolic blood pressure [17].
261 In the present study, despite the availability of smoking
262 cessation treatments, one-fifth of patients continued
263 smoking. Previous studies have shown that smoking ces-
264 sation reduces the likelihood of recurrent cardiovascular
265 events in patients with coronary heart disease [18]. How-
266 ever, quitting smoking is physiologically and psychologi-
267 cally very challenging and many patients are not suitable
268for pharmacologic smoking cessation intervention due to
269history of anxiety and depression. More ‘‘holistic-type’’
270programs not using pharmacological intervention have
271reported significant improvements in smoking cessation.
272Therefore, a dedicated smoking cessation program in
273conjunction with the risk factor clinic may be warranted
274[19].
275Obesity has been shown to have a negative impact on
276other cardiovascular risk factors including dyslipidemia,
277raised blood pressure and type II diabetes [20]. Weight loss
278is associated with improvements in blood pressure, total
279cholesterol, LDLc, triglycerides, glucose and HDLc.
280Therefore, weight loss is critical for reducing the cardio-
281vascular risk profile of obese patients [20]. Over half of the
282patients attending the clinic were obese, significantly but
283not surprisingly higher than the Irish population average of
28425 % [22]. These findings are similar to that of the latest
285EUROASPIRE where 83 % of patients had a
286BMI C 25 kg/m
2
and 38 % had C30 kg/m
2
. Significant
287improvements in BMI were not observed in those without
288CHD. However, weights actually increased in those with
289CHD during clinic visits. This may be due to an initial
290change in patients’ weight once CHD was diagnosed and a
291relaxation or refocus once other risk factor management
292was in place.
293Previous studies that have adopted intense exercise
294interventions have been successful [20]. Drug interventions
295to achieve weight loss may have adverse side effects with
296only modest effects on weight loss and therefore were not
297considered as a first-line treatment for obese patients at our
298clinic [23]. Current medical focus is placed more on the
299management of the complications of obesity such as
300hypertension, dyslipidemia and diabetes rather than the
301source of many of these problems which is obesity itself. In
302clinical practice, cardiovascular risk factors governed by
303lifestyle such as smoking, BMI and waist circumference
304are the most difficult to manage.
305In summary, our retrospective audit highlights many
306successes and a number of apparent failures. Some expla-
307nations for both have been considered. It is particularly
308important to note that in modern clinical practice with the
309increasing awareness about cardiovascular risk factors, the
310best results occur in the community. Patients whose risk
311factors are well controlled rarely reach the hospital risk
312factor clinic. Thus, this audit pertains to the patients who
313were not ‘‘cherry picked’’ for success. As observed in other
314studies, the cardiovascular risk factors that were managed
315primarily through medications were better controlled than
316those primarily improved by lifestyle changes. More
317emphasis needs to be placed on weight reduction and
318smoking cessation therapies, as successful management of
319these risk factors have been shown to lead to improvements
320in the other cardiovascular risk factors. The
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321 EUROACTION preventative cardiology program shows
322 that with a professional, comprehensive and multidisci-
323 plinary program, lifestyle changes can be achieved leading
324 to weight loss, reduced central obesity, reduced blood
325 pressure and improved blood cholesterol concentrations.
326 Barriers to prevention programs such as these include lack
327 of time, prescribing costs and poor patient compliance.
328 However, the feasibility of such programs should be further
329 explored as they address the risk factors most clinicians
330 find difficult to manage.
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